Cargando…
Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238999/ https://www.ncbi.nlm.nih.gov/pubmed/34183689 http://dx.doi.org/10.1038/s41598-021-92757-0 |
_version_ | 1783714992347938816 |
---|---|
author | Zhang, Xi An, Xiaocui Shi, Lei Yang, Xueliang Chen, Yunru Liu, Xiaojing Li, Jianzhou Ye, Feng Lin, Shumei |
author_facet | Zhang, Xi An, Xiaocui Shi, Lei Yang, Xueliang Chen, Yunru Liu, Xiaojing Li, Jianzhou Ye, Feng Lin, Shumei |
author_sort | Zhang, Xi |
collection | PubMed |
description | The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy. |
format | Online Article Text |
id | pubmed-8238999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82389992021-07-06 Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years Zhang, Xi An, Xiaocui Shi, Lei Yang, Xueliang Chen, Yunru Liu, Xiaojing Li, Jianzhou Ye, Feng Lin, Shumei Sci Rep Article The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy. Nature Publishing Group UK 2021-06-28 /pmc/articles/PMC8238999/ /pubmed/34183689 http://dx.doi.org/10.1038/s41598-021-92757-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhang, Xi An, Xiaocui Shi, Lei Yang, Xueliang Chen, Yunru Liu, Xiaojing Li, Jianzhou Ye, Feng Lin, Shumei Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years |
title | Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years |
title_full | Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years |
title_fullStr | Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years |
title_full_unstemmed | Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years |
title_short | Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years |
title_sort | baseline quantitative hbcab strongly predicts undetectable hbv dna and rna in chronic hepatitis b patients treated with entecavir for 10 years |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238999/ https://www.ncbi.nlm.nih.gov/pubmed/34183689 http://dx.doi.org/10.1038/s41598-021-92757-0 |
work_keys_str_mv | AT zhangxi baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT anxiaocui baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT shilei baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT yangxueliang baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT chenyunru baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT liuxiaojing baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT lijianzhou baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT yefeng baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT linshumei baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years |